chartexchange

IBRX270416C00011000
IBRX Apr 16 2027 11.00 Call
optionOPRA

EODOct 15, 2026
2.48USD-0.800%(-0.02)1Vol98OI
Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
11
Expiration
Apr 16, 2027
DTE
178d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.05-80.00%541,377
Oct 30, 202610d$0.25-28.57%231,984
Nov 6, 202617d$0.45-18.18%34417
Nov 13, 202624d$0.80-20.00%9441
Nov 20, 202631d$0.55-37.50%6305,915
Nov 27, 202638d$1.02+27.50%623
Dec 18, 202659d$1.35+0.00%3621
Jan 15, 202787d$1.15-32.35%39216,211
Mar 19, 2027150d$1.60-41.82%11921
Apr 16, 2027178d$2.48-0.80%198
May 21, 2027213d$3.00-3.23%1420
IBRX Nearby Strikes · Apr 16, 2027
StrikeLastChangeVolOpen IntMoneyness
5 C$5.70+9.62%225ITM
6 C$3.90+30.00%10ITM
7 C$4.48+0.00%1111ITM
8 C$4.16+69.80%2096ITM
9 C$3.40-12.82%142OTM
10 C$2.10-27.84%8135OTM
11 C$2.48-0.80%198OTM
12 C$1.80-25.00%180176OTM
13 C$2.11+24.12%4045OTM
14 C$2.10+22.81%2021OTM
15 C$1.10-43.59%148OTM
16 C$1.35+0.00%200250OTM
17 C$0.75-34.21%6100OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.